Mandate

VINGE ADVISES FORTUM with SALE OF Fortum Distribution

March 16, 2015

Fortum and a consortium consisting of the First Swedish National Pension Fund (12.5%), the Third Swedish National Pension Fund (20%) and Folksam (17.5%) as well as the international infrastructure investment company, Borealis Infrastructure Management Inc. (50%) signed a purchase agreement in respect of Fortum Distribution AB, a company which constitutes Fortum’s electricity network operation in Sweden. 

The total purchase price is EUR 6.6 billion (equivalent to approximately SEK 60.6 billion) on a cash free/debt free basis. Fortum anticipates that the transaction will be completed during the second quarter of 2015, provided that the requisite regulatory approvals and the agreement’s customary conditions are fulfilled. Fortum anticipates reporting a non-recurring revenue item for the second quarter of 2015 of approximately EUR 4.4 billion, equivalent to approximately EUR 5 per share.

Vinge’s team consisted of responsible partner Johan Göthberg together with associates Gustav Jönsson and Andrea Jägerstedt (M&A), partners Jonas Eklund and Carl Johan af Petersens and Fredrik Lundblom as well as associates Emilie Håkansson, Helena Wanhainen and Johan Cederblad (regulatory). 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025